Sanofi Quick Ratio 2010-2023 | SNY
Historical quick ratio values for Sanofi (SNY) over the last 10 years.
| Sanofi Quick Ratio Historical Data |
| Date |
Current Assets - Inventory |
Current Liabilities |
Quick Ratio |
| 2023-12-31 |
$22.73B |
$26.19B |
0.87 |
| 2023-09-30 |
$0.00B |
|
0.00 |
| 2023-06-30 |
$21.82B |
$27.00B |
0.81 |
| 2023-03-31 |
$0.00B |
|
0.00 |
| 2022-12-31 |
$26.41B |
$25.25B |
1.05 |
| 2022-09-30 |
$0.00B |
|
0.00 |
| 2022-06-30 |
$7.91B |
$23.48B |
0.34 |
| 2022-03-31 |
$0.00B |
|
0.00 |
| 2021-09-30 |
$0.00B |
|
0.00 |
| 2021-06-30 |
$24.39B |
$23.05B |
1.06 |
| 2021-03-31 |
$0.00B |
|
0.00 |
| 2020-09-30 |
$0.00B |
|
0.00 |
| 2020-03-31 |
$0.00B |
|
0.00 |
| 2019-09-30 |
$0.00B |
|
0.00 |
| 2019-03-31 |
$0.00B |
|
0.00 |
| 2018-03-31 |
$0.00B |
|
0.00 |
| 2017-12-31 |
$22.08B |
$17.47B |
1.26 |
| 2017-09-30 |
$0.00B |
|
0.00 |
| 2017-06-30 |
$21.81B |
$18.76B |
1.16 |
| 2017-03-31 |
$0.00B |
|
0.00 |
| 2016-12-31 |
$21.91B |
$18.19B |
1.21 |
| 2016-09-30 |
$0.00B |
|
0.00 |
| 2016-06-30 |
$17.25B |
$17.22B |
1.00 |
| 2016-03-31 |
$0.00B |
|
0.00 |
| 2015-09-30 |
$0.00B |
|
0.00 |
| 2015-06-30 |
$16.44B |
$18.03B |
0.91 |
| 2014-06-30 |
$18.64B |
$19.48B |
0.96 |
| 2013-06-30 |
$18.22B |
$17.80B |
1.02 |
| 2012-06-30 |
$19.10B |
$20.66B |
0.92 |
| 2012-03-31 |
$0.00B |
|
0.00 |
| 2011-12-31 |
$20.62B |
$18.92B |
1.09 |
| 2011-09-30 |
$0.00B |
|
0.00 |
| 2011-06-30 |
$23.56B |
$23.10B |
1.02 |
| 2011-03-31 |
$0.00B |
|
0.00 |
| 2010-12-31 |
$29.29B |
$15.62B |
1.88 |
| 2010-09-30 |
$0.00B |
|
0.00 |
| 2010-06-30 |
$25.36B |
$15.40B |
1.65 |
| 2010-03-31 |
$0.00B |
|
0.00 |
| 2009-12-31 |
$27.10B |
$17.29B |
1.57 |
| 2009-09-30 |
$0.00B |
|
0.00 |
| 2009-06-30 |
$19.42B |
$14.69B |
1.32 |
| 2009-03-31 |
$0.00B |
|
0.00 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$114.819B |
$46.611B |
|
Sanofi-Aventis manufactures & markets prescription drugs across countries. It focuses on major therapeutic areas such as multiple sclerosis, cardiovascular, immunology, neurology, oncology, rare blood disorders & diabetes, etc. By taking Genzyme Corporation as a subsidiary, it added products like Cerezyme, Myozyme/Lumizyme & Fabrazyme to its portfolio. Sanofi has become a major player in the CHC sector. It acquired many companies i.e. Ablynx & Bioverativ, Synthorx & Principia & Translate Bio and Kadmon. It has collaborated with companies like Regeneron among others. It develops and markets Dupixent, Kevzara & Libtayo in collaboration with Regeneron. Sanofi, along with Regeneron, is now solely responsible for Praluent marketing in & outside the U.S. Sanofi operates through 3 Global Business Units: Specialty Care (neurology & immunology, rare diseases, rare blood disorders & oncology), Vaccines & General Medicines (diabetes, cardiovascular & established products) and Consumer Healthcare, a standalone unit.
|
